Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Subspecialties

Urothelial carcinoma: histologic subtypes and divergent differentiation

August 2026—Recognizing and reporting histologic subtypes and divergent differentiation in urothelial carcinoma is critical for diagnosis, prognosis, and treatment. “Ideally, you want to mention the subtype histologies in pathology reports and quantify the amount,” said Francesca Khani, MD, associate professor in the Department of Pathology and Laboratory Medicine and in the Department of Urology, Weill Cornell Medicine. In a CAP25 session last fall, Dr. Khani spoke of the mimics of benign entities and of other malignancies.

Views on AI use for lab test orders and reports

August 2026—Would artificial intelligence as an aid in ordering laboratory tests and making reports understandable to patients be a worry or a welcome step? In a June 2 online roundtable led by CAP TODAY publisher Bob McGonnagle, a Compass Group member shared what he learned about an Epic pilot, and that launched the following conversation about the clinical laboratory and pathology reports that could be made easier for patients to understand. One participant’s view: “proceed with caution.”

Student-led workshops introduce pathology to peers

August 2026—A series of hands-on or role-playing workshops created by pathology student interest group leaders at a California medical school introduced pathology to dozens of students who would have otherwise completed their curriculum without that exposure.

AMP case report: Therapy-related acute myeloid leukemia in a patient with BRCA1-positive breast cancer and a DDX41 possibly germline variant

August 2026—The 2022 World Health Organization and International Consensus Classification frameworks recognize several well-defined myeloid neoplasm categories that arise in the setting of inherited genetic predisposition. These entities are grouped according to associated clinical features and include myeloid neoplasms with germline predisposition in the absence of antecedent platelet abnormalities or organ dysfunction (e.g. CEBPA, DDX41, and TP53), those associated with inherited platelet disorders (e.g. RUNX1, ANKRD26, and ETV6), and disorders linked to underlying or potential organ dysfunction.

Cytopathology in focus—Predictive markers in cytopathology: programmed death ligand-1

August 2026—Although cytologists and cytopathologists expend considerable effort in screening, risk stratification, diagnosis, staging, and prognostication, clinicians are increasingly demanding ancillary testing that predicts response or resistance to the broad range of therapeutic agents available to them. In advanced-stage non-small cell lung carcinoma, these therapies include tyrosine kinase and other small-molecule inhibitors, bispecific antibodies, and antibody-drug conjugates.

Cytopathology in focus—What sets pediatric cytology apart?

August 2026—Pediatric pathology remains a relatively small subspecialty within anatomic pathology. The American Board of Pathology since 1990 has issued only 648 subspecialty certificates in pediatric pathology, and between 2020 and 2024, only 14 to 21 candidates sat for the pediatric pathology certifying examination each year.

Time to improve preeclampsia screening

July 2026—Among its many peculiarities, medicine dwells in interstitial spaces—between seeing a problem and addressing it; between the (in)actions of one specialty and another; between practice and practice guidelines; between overtreatment and targeted treatment; between widespread access and boutique care.

Hematopathology’s move to the Fellowship Match

July 2026—When Neha Gupta, MD, attended a fellowship fair early in her second year of residency, she was caught off guard by the number of programs already accepting applications from her peers. It was only March, and she had been told she could apply for her fellowship in late summer.

Assessing neoadjuvant therapy response in lung resection specimens

July 2026—An International Association for the Study of Lung Cancer panel provided recommendations in 2020 on how to process lung cancer resection specimens and define pathologic response after neoadjuvant therapy. They were intended as guidance for clinical trials but offered as a suggestion for good clinical practice.

MARKETPLACE

TRENDING